Scientific Evidence Supporting CDS22
The CDS22-formula has been studied for more than 20 years, with over 200 peer-reviewed publications and 80 controlled clinical trials demonstrating its safety, efficacy, and unique benefits for gut health. The De Simone Formulation is recognised by name in the official guidelines of both the American Gastroenterology Association (AGA) and the European Crohn’s and Colitis Organization (ECCO).
Evidence-Based Benefits
- Supports the management of intestinal dysbiosis and restoration of gut flora balance.
- Provides nutritional support for individuals with IBD, Crohn’s disease, ulcerative colitis, IBS, and antibiotic-related gut disturbance.
- Clinically validated for gut barrier integrity, immune function, and overall digestive resilience.
Why the De Simone Formulation Is Unique
The CDS22-formula’s efficacy stems from its proprietary combination of eight bacterial strains cultivated and stabilised in precise ratios to ensure viability and synergistic effects. These strains are stored in master cell banks to maintain quality and genetic consistency.
To review key studies, visit the official CDS22 global science library.